ArticleInternational journal of women's health2026
Association of Body Mass Index with Tumor-Infiltrating Lymphocytes and Treatment Response in Early HER2-Positive Breast Cancer.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune-related biomarkers such as stromal tumor-infiltrating lymphocytes (TILs) are associated with response to neoadjuvant therapy in HER2+ breast cancer. Host-related factors, including BMI, may influence the tumor immune microenvironment and modify the predictive value of immune infiltration. Methods: In this retrospective cohort study, we evaluated associations between BMI, stromal TIL density, selected immune checkpoint markers (PD-1 and TIM-3), leptin receptor (Ob-R) expression, and pathological complete response (pCR) in patients with early-stage HER2+ breast cancer treated with neoadjuvant HER2-targeted therapy. Results: Of 101 patients analyzed, 48.0% had a BMI ≥25 kg/m Conclusion: Host-related factors, as captured by BMI, may influence the tumor immune microenvironment and predictive value of immune biomarkers in early-stage HER2-positive breast cancer. As the study was exploratory, these observations warrant further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.